Jeff George took over as head of Sandoz, Novartis's generics business, in late 2008. With a big push in emerging markets, a leadership position in biosimilars and an expanded focus on injectables, he explained to Scrip's companies editor Eleanor ...
The fundraising that saved Amarin from financial woes last years appear to have given the company a new lease of life. Its interim CEO Dr
Declan Doogan
told Scrip of his confidence for the company's future.
Since Amarin terminated the development ...
Developing relationships with medicine regulators in China and India is just one of the challenges facing Emer Cooke, the international face of the European Medicines Agency (EMA), Scrip's Elizabeth Sukkar finds.
The first time I heard
Emer ...
As Allon Therapeutics prepares to advance its lead drug candidate, davunetide intranasal (formerly AL-108), into proof-of-concept trials for progressive supranuclear palsy (PSP), its chief medical officer,
Dr Steven Whitaker
told Scrip of the ...
